{"nctId":"NCT04328467","briefTitle":"Pre-exposure Prophylaxis for SARS-Coronavirus-2","startDateStruct":{"date":"2020-04-06","type":"ACTUAL"},"conditions":["COVID-19","Corona Virus Infection","ARDS","Acute Respiratory Distress Syndrome"],"count":1483,"armGroups":[{"label":"Intervention Once Weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Hydroxychloroquine"]},{"label":"Intervention Twice Weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Hydroxychloroquine"]},{"label":"Control Group","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Hydroxychloroquine","otherNames":["Plaquenil"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- A healthcare worker at high risk for COVID-19 exposure (defined below):\n\n* Persons primarily working in emergency departments (physicians, nurses, ancillary staff, triage personnel)\n* Persons primarily working in intensive care units (physicians, nurses, ancillary staff, respiratory therapists)\n* Persons performing aerosol generating procedures (i.e. anesthesiologists, nurse anesthetists (CRNAs)\n* First responders (i.e. EMTs, paramedics)\n\nExclusion Criteria:\n\n* Active COVID-19 disease\n* Prior COVID-19 disease\n* Current fever, cough, shortness of breath\n* Allergy to chloroquine or hydroxychloroquine\n* Prior retinal eye disease\n* Known Chronic Kidney disease, Stage 4 or 5 or dialysis\n* Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency\n* Weight \\<40 kg\n* Prolonged QT syndrome\n* Current use of hydroxychloroquine, chloroquine, or cardiac medicines of flecainide, amiodarone, digoxin, procainamide, or propafenone\n* Current use of medications with known significant drug-drug interactions: artemether, lumefantrine, mefloquine, tamoxifen, or methotrexate.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"COVID-19-free Survival","description":"Outcome reported as the number of participants in each arm who are COVID-19-free at the end of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"464","spread":null},{"groupId":"OG001","value":"468","spread":null},{"groupId":"OG002","value":"454","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Confirmed SARS-CoV-2 Detection","description":"Outcome reported as the number of participants in each arm who have a confirmed SARS-CoV-2 infection during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Possible COVID-19 Symptoms","description":"Outcome reported as the count of participants in each arm who report COVID-19-related symptoms during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of All-cause Study Medicine Discontinuation","description":"Outcome reported as the count of participants in each arm who discontinue study medication use for any reason during treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"158","spread":null},{"groupId":"OG002","value":"133","spread":null}]}]}]},{"type":"SECONDARY","title":"Ordinal Scale of COVID-19 Disease Maximum Severity if COVID-19 Diagnosed at Study End","description":"Participants will self-report COVID-19 status on an ordinal scale as follows: No illness (score=1), Illness with outpatient observation (score=2), Hospitalization (or post-hospital discharge) (score=3), or Hospitalization with ICU stay or death (score=4). Possible scores range from 1-4 with higher scores indicating greater disease severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":"NA"},{"groupId":"OG002","value":"1","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Incidence of Hospitalization for COVID-19 or Death","description":"Outcome reported as the number of participants in each arm who are hospitalized or expire due to COVID-19 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Possible Study Medication-related Side Effects","description":"Outcome reported as the number of participants in each arm who experience possible medication-related side effects during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"168","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":494},"commonTop":[]}}}